NVTAG

Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg

25

The EU-HTA regulation and its impact on access to innovative technologies

12 October 2023

NVTAG

Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg

25

Anke van Engen

IQVIA

EU HTA Regulation – What, Why, When?

October 12th 2023

Anke van Engen, Senior Principal, IQVIA

How familiar are you with the EU HTA regulation?



How prepared are we in the Netherlands to successfully implement the EU HTA regulation?



NVTAG

Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg

25

Suzette Matthijsse

Lumanity

Impact of the EU HTA Regulation

Global industry perspective

12 October 2023

Presented by: Suzette Matthijsse

Lumanity

Do you feel you are well informed and know enough about the new EU HTA Regulation?



Are you clear on how the EU HTA regulation will affect your organisation's EU HTA operations?



Are you encountering any obstacles within your organisation to plan for the EU HTA Regulation's full implementation?



NVTAG

Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg

25

Anne Willemsen

ZIN, EUnetHTA

Zorginstituut Nederland

Impact of EU-HTA Regulation

Decision-making perspective

Anne Willemsen, Dutch National Healthcare Institute (Zorginstituut Nederland)

Co-Chair JCA Subgroup under the HTA Coordination Group

12 october 2023

| Van goede zorg verzekerd |

What is in your view the biggest challenge in the national preparation for the EU HTA Regulation?

66 responses

Omitting a national PICO in the consolidated PICOs for a EU JCA is …



NVTAG

Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg

25

Rick Vreman

Roche

Perspective on EU HTA implementation in NL

A discussion on challenges and opportunities

NVTAG Symposium on EU HTA

Rick Vreman, Patient access manager & policy lead

Roche Netherlands B.V.

M-NL-00001877

12-10-2023

On which aspect do you think EU HTA can help us do better regarding reimbursement decision making in the Netherlands?



How long do you believe a Dutch assessment should take after the JCA report is available?



NVTAG

Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg

25

Panel Discussion

Maurice Driessen, NVTAG board member



Do you have questions for the panel?

7 responses

What will be the biggest challenge for implementing the EU HTA regulation?

The statement was made we just have to start and try, but on the other hand the statement was made of dossier is deemed incomplete you get only one chance...is that realistic in the 1st period?

CEA and BIA are left at the responsibility of the local authorities but are not missing there an opportunity to harmonize across MS? E.g use of R

To what extend is there collaboration with the EMA? Especially given that the EMA has become more lenient for surrogate outcomes and single arm trials for ultra orphan drugs?

I have rarely seen all stakeholders (regulators, pharma, consultancy) in such positive harmony. What am I missing?

What is the most important question regarding methods that needs to be answered to increase the success of implementing the regulation?

Would it be possible to include (like the EMA process) one or two moments of questions and answers from assessors to pharmaceutical company?